MX344972B - Oligonucleotidos inmunoestimulantes. - Google Patents

Oligonucleotidos inmunoestimulantes.

Info

Publication number
MX344972B
MX344972B MX2013005544A MX2013005544A MX344972B MX 344972 B MX344972 B MX 344972B MX 2013005544 A MX2013005544 A MX 2013005544A MX 2013005544 A MX2013005544 A MX 2013005544A MX 344972 B MX344972 B MX 344972B
Authority
MX
Mexico
Prior art keywords
immunostimulatory oligonucleotides
compositions
disclosed
along
nucleic acids
Prior art date
Application number
MX2013005544A
Other languages
English (en)
Other versions
MX2013005544A (es
Inventor
B Lipford Grayson
Fraser Christopher
Original Assignee
Selecta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selecta Biosciences Inc filed Critical Selecta Biosciences Inc
Publication of MX2013005544A publication Critical patent/MX2013005544A/es
Publication of MX344972B publication Critical patent/MX344972B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones que incluyen ácidos nucleicos inmunoestimulantes, junto con el uso de dichas composiciones para inducir respuestas inmunes.
MX2013005544A 2010-11-16 2011-11-16 Oligonucleotidos inmunoestimulantes. MX344972B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41419410P 2010-11-16 2010-11-16
PCT/US2011/061056 WO2012068295A1 (en) 2010-11-16 2011-11-16 Immunostimulatory oligonucleotides

Publications (2)

Publication Number Publication Date
MX2013005544A MX2013005544A (es) 2013-09-26
MX344972B true MX344972B (es) 2017-01-12

Family

ID=46084406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005544A MX344972B (es) 2010-11-16 2011-11-16 Oligonucleotidos inmunoestimulantes.

Country Status (14)

Country Link
US (1) US8546550B2 (es)
EP (1) EP2640426B1 (es)
JP (3) JP5933577B2 (es)
KR (1) KR20130116890A (es)
CN (2) CN103347542B (es)
AU (2) AU2011329850B2 (es)
BR (1) BR112013012195A2 (es)
CA (1) CA2817746A1 (es)
DK (1) DK2640426T3 (es)
EA (1) EA030096B1 (es)
ES (1) ES2569857T3 (es)
IL (2) IL226299A (es)
MX (1) MX344972B (es)
WO (1) WO2012068295A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CN110743008A (zh) 2013-03-14 2020-02-04 哈佛大学的校长及成员们 基于纳米颗粒的组合物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105936906B (zh) * 2013-11-08 2019-06-21 上海交通大学 被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
MA47016A (fr) 2015-10-22 2018-08-29 Modernatx Inc Vaccins contre les virus respiratoires
CA3004363A1 (en) * 2015-11-06 2017-05-11 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same
CN108014333B (zh) * 2017-10-11 2020-10-20 江苏省农业科学院 动物用粘膜靶向免疫增强剂及其在兽用疫苗中的应用
US20200390807A1 (en) * 2018-02-20 2020-12-17 University Of Florida Research Foundation, Incorporated Composition and method for targeting natural killer cells in immunotherapy to overcome tumor suppression with manganese dioxide nanoparticles
CA3093709C (en) 2018-03-16 2024-03-26 Zoetis Services Llc Peptide vaccines against interleukin-31
EP3824891A4 (en) * 2018-07-19 2022-07-13 The Research Foundation for Microbial Diseases of Osaka University LIPID PARTICLES WITH CPG OLIGODESOXYNUCLEOTIDE TYPE A
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN114796476B (zh) * 2021-09-24 2024-10-11 中国医学科学院医学生物学研究所 一种亚单位疫苗新型核酸佐剂系统及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
CN1604795B (zh) * 2001-08-17 2010-05-26 科勒制药股份公司 具有提高的活性的组合基序免疫刺激寡肽
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
ES2381309T3 (es) * 2002-12-23 2012-05-25 Dynavax Technologies Corporation Secuencia de oligonucleótidos inmunoestimuladores y métodos para usar los mismos
CN1296378C (zh) * 2004-05-17 2007-01-24 中国人民解放军第三军医大学 高免疫活性 CpG－S ODN 和拮抗 CpG－S ODN 作用的 CpG－N ODN 的基因序列及其应用
CA2579957A1 (en) * 2004-09-14 2006-03-23 Nanodel Technologies Gmbh Delivery vehicle containing nanoparticles
CN101160401A (zh) * 2005-02-24 2008-04-09 科勒制药集团公司 免疫刺激寡核苷酸
ES2389112T3 (es) * 2006-05-31 2012-10-23 Toray Industries, Inc. Oligonucleótido inmunoestimulador y aplicación farmacéutica del mismo
US9023395B2 (en) * 2007-04-13 2015-05-05 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
EP3424525A1 (en) * 2007-10-12 2019-01-09 Massachusetts Institute Of Technology Vaccine nanotechnology
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
JP2012524780A (ja) * 2009-04-21 2012-10-18 セレクタ バイオサイエンシーズ インコーポレーテッド Ｔｈ１バイアス応答をもたらす免疫ナノ治療薬（Ｉｍｍｕｎｏｎａｎｏｔｈｅｒａｐｅｕｔｉｃｓ）
CA2771863A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help

Also Published As

Publication number Publication date
AU2011329850A1 (en) 2013-06-06
EP2640426B1 (en) 2016-02-03
IL252061A0 (en) 2017-07-31
BR112013012195A2 (pt) 2018-07-10
CN105327363A (zh) 2016-02-17
AU2011329850B2 (en) 2017-03-02
US8546550B2 (en) 2013-10-01
DK2640426T3 (en) 2016-05-02
ES2569857T3 (es) 2016-05-12
CA2817746A1 (en) 2012-05-24
KR20130116890A (ko) 2013-10-24
AU2017203714A1 (en) 2017-06-22
JP6203897B2 (ja) 2017-09-27
JP5933577B2 (ja) 2016-06-15
EP2640426A4 (en) 2014-11-05
CN103347542B (zh) 2015-09-16
CN103347542A (zh) 2013-10-09
IL226299A0 (en) 2013-07-31
EP2640426A1 (en) 2013-09-25
EA201300585A1 (ru) 2013-11-29
JP2014501504A (ja) 2014-01-23
EA030096B1 (ru) 2018-06-29
WO2012068295A1 (en) 2012-05-24
JP2018023389A (ja) 2018-02-15
US20120213812A1 (en) 2012-08-23
JP2016189777A (ja) 2016-11-10
MX2013005544A (es) 2013-09-26
IL226299A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
MX344972B (es) Oligonucleotidos inmunoestimulantes.
IL273838A (en) Peptide and oligonucleotide conjugates, preparations containing them and their uses
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
IL262242A (en) Targeted nucleic acid coupling preparations
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
WO2015085318A3 (en) Targeted adaptive vaccines
MX361862B (es) Composiciones y métodos que comprenden variante de enzima lipolítica.
MX384253B (es) Composiciones y metodos que comprenden una variante de enzima lipolitica
IL247469B (en) Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses
MX371018B (es) Polipéptidos que tienen actividad de transgalactosilación.
GB2537077A (en) Methods for sequencing nucleic acids
MX2012007710A (es) Alfa-amilasas.
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
GB201218752D0 (en) Mineral complex, compositions thereof, and methods of using the same
MX340259B (es) Formulaciones de testosterona.
WO2014096992A8 (en) Acetyl transferases and their use for producing carotenoids
IN2014DN09085A (es)
ZA201404199B (en) Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
ZA201507774B (en) Novel vaccine compositions comprising immunostimulatory oligonucleotides
MY165088A (en) Pharmaceutical compositions comprising alisporivir
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.

Legal Events

Date Code Title Description
FG Grant or registration